期刊文献+

HPLC法测定达沙替尼含量及有关物质 被引量:3

Determination of Dasatinib and related substances by HPLC
下载PDF
导出
摘要 目的 高效液相色谱法测定达沙替尼原料药的含量及其有关物质。方法 采用YMC Pack Pro C18色谱柱,以流动相A〔50mM醋酸铵溶液pH 5.25∶乙腈∶甲醇(90∶5∶5)〕和流动相B〔50mM醋酸铵溶液pH 5.25∶乙腈∶甲醇(10∶85∶5)〕进行梯度洗脱,流速为1.2mL.min-1,检测波长为320nm,柱温为35℃,进样体积10uL。结果 在选定的色谱条件下,样品和各中间体分离度良好;在5~50μg.mL-1范围内线性关系良好,最低检测线为0.015μg.mL-1。结论 所用方法灵敏、准确、可靠。 OBJECTIVE To establish a method for determination of dasatinib and related substances by HPLC. METHODS The chromatography was carried out with YMC Pack Pro C18 column. Gradient elution,mobile phase A ammonium acetate solution (50mM, pH 5.25) : acetonitrile: methanol = 90: 5: 5 ; mobile phase B ammonium acetate solution (50mM,pH 5.25) : acetonitrile: methanol = 10:85:5. The flow rate was 1.2mL· min^-1 ,the detection wavelength was 320nm,the column temperature was 35℃ and the injection volume was 10uL RESULTS Under the selected chromatographic condition, the sample could separated well with the three intermediates. The calibration curve for Dasatinib was linear in the range of 5 -50μg·mL^-1. The detection limit for Dasatinib was 0. 015μg·mL^-1. CONCLUSION The method is svecific, simvle, sensitive and can be used for quality control of Dasatinib.
出处 《海峡药学》 2013年第7期72-74,共3页 Strait Pharmaceutical Journal
关键词 达沙替尼 高效液相色谱 中间体 含量 Dasatinlb I-IPLC Intermediates Assay
  • 相关文献

参考文献5

二级参考文献40

  • 1燕芳龙,管清香,华蕾,王恩思.地拉韦啶及有关物质的HPLC测定[J].中国医药工业杂志,2006,37(7):486-487. 被引量:3
  • 2SHAH N P. Dasatinib [ J ]. Drugs Today, 2007,43 (1):5.
  • 3LOMBARDO L J, LEE F Y, CHEN P, et al. Discovery of N-( 2-chloro-6-methyl-pheny 1 ) -2-(6-(4-( 2- hydroxyethyl )-piperazin-1-yl )-2-methylpyrimidin- 4-ylamino) thiazole-5-carboxamide ( BMS-354825 ), a dual src/abl kinase inhibitor with potent antitumor activity in preclinical assays[ J]. J Med Chem,2004, 47 (27) : 6658 - 6661.
  • 4CHEN B, DROGHINI R, LAJEUNESSE J, et al. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors: WO, 2005/ 077945A2 [ P]. 2005 - 08 - 25.
  • 5FERNANDEZ F, GARCIA-MERA X, MORALES M, et al. A short, efficient synthesis of substituted uracil : an indane carbocyclic nucleoside [ J ]. Synthesis,2001 ( 2 ) :239 - 242.
  • 6Das J, Chen P, Norris D. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N- (2-chloro-6-methylphenyl) -2-[[6-[4- (2-hydroxyethyl) - 1-piperazinyl] -2 -methyl-4- pyrimidinyl]amino]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor [J]. J Med Chem, 2006, 49(23) : 6 819.
  • 7Mcintyre JA, Castaner J, Bayes M. Dasatinib: treatment of leukemia treatment of solid tumors Bcr-Abl and Src kinase inhibitor[J]. Drugs of the Future, 2006, 31 (4) : 291.
  • 8Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N- (2-chloro-6-methylphenyl) - 2- [ [6- [4-2-hydroxyethy-l-piperazinyl] -2- methyl-4- pyrimidinyl] amino] - 1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor [J] . J Med Chem, 2006, 49 (23) : 6819-6832.
  • 9Mclntyre JA, Castaner J, Bayes M. Dasatinib: treatment of leukemia, treatment of solid tumors, Bcr-Abl and Src kinase inhibitor [J]. Drugs Future, 2006, 31 (4) : 291-303.
  • 10Mhaske DV, Dhaneshwar SR. Stability indicating HPTLC and LC determination of dasatinib in pharmaceutical dosage form [J]. Chromatographia, 2007, 66 (1-2) : 95-102.

共引文献28

同被引文献15

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部